EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in China

Jianying Zhou iD, Yongsheng Wang, Jiewen Peng, Ke-Jing Tang, Jun Wu, Yajuan Chen, Zhiyi Xue, Yi-Long Wu iD

Lung Cancer: Targets and Therapy · 2026-02 · Volume 17 · 1-10

DOI: 10.2147/lctt.s555262 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Lung Cancer: Targets and Therapy, 2026-02. Verfasst von Jianying Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, Peop…. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

EGFR mutation-positiveNSCLCafatinibreal-world evidence

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
  • Division of Thoracic Tumor Multimodality Treatment, Cancer Center, and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
  • Department of Oncology, Zhongshan City People's Hospital, Zhongshan, Guangdong, People's Republic of China.
  • Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China.
  • Department of Thoracic Surgery, Hainan Cancer Hospital, Haikou, Hainan, People's Republic of China.
  • Clinical Development and Medical Affairs, Boehringer Ingelheim (China) Investment Co., Ltd., Shanghai, People's Republic of China.

ORCID-Profile: Jianying Zhou, Yi-Long Wu

Zitieren

APA

Zhou, J., Wang, Y., Peng, J., Tang, K. J., Wu, J., Chen, Y., Xue, Z., & Wu, Y. L. (2026). Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in China. Lung Cancer: Targets and Therapy, Volume 17, 1-10. https://doi.org/10.2147/lctt.s555262

Vancouver

Zhou J, Wang Y, Peng J, Tang KJ, Wu J, Chen Y, et al. Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in China. Lung Cancer: Targets and Therapy. 2026;Volume 17:1-10. doi:10.2147/lctt.s555262

BibTeX
@article{Zhou2026,
  author = {Zhou, Jianying and Wang, Yongsheng and Peng, Jiewen and Tang, Ke-Jing and Wu, Jun and Chen, Yajuan and Xue, Zhiyi and Wu, Yi-Long},
  title = {Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in China},
  journal = {Lung Cancer: Targets and Therapy},
  year = {2026},
  volume = {Volume 17},
  pages = {1--10},
  doi = {10.2147/lctt.s555262}
}
Kostenlos starten →